Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Banking & Insurance

UBS Returns to Contingent Capital Market Amid Legal Uncertainty

Andreas Sommer by Andreas Sommer
January 5, 2026
in Banking & Insurance, Bonds, European Markets
0
UBS Stock
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

Swiss banking giant UBS has launched its first Additional Tier 1 (AT1) bond issuance since September 2025, testing investor appetite in a complex environment. The bank is bringing two dollar-denominated tranches to market with coupons exceeding 7%, a move that coincides with pending litigation over the wiped-out Credit Suisse AT1 bonds and awaits promised regulatory easing.

Key details of the new issuance:

  • Two AT1 tranches denominated in US dollars
  • Coupons set at 7.125% (callable 2031) and 7.5% (callable 2036)
  • The first global bank AT1 transaction of 2026
  • Placement proceeds amidst ongoing court cases

A Landscape Shaped by Courts and Legislators

This capital raise occurs during a period of significant legal and regulatory fragility. On October 1, 2025, Switzerland’s Federal Administrative Court overturned the financial regulator’s decision to write down $17 billion worth of Credit Suisse AT1 bonds. The Swiss Financial Market Supervisory Authority (FINMA) has appealed the ruling, leaving the final outcome uncertain.

In parallel, the Swiss parliament is debating regulatory relaxations. These could eventually allow UBS to use AT1 instruments instead of pure equity to capitalize its foreign subsidiaries. Investor sentiment showed a positive shift in mid-December, with UBS shares jumping to CHF 35.16—their highest level since 2008. The stock currently trades at CHF 36.94.

Should investors sell immediately? Or is it worth buying UBS?

Market Experts Advise Caution

Analysts are tempering expectations despite the deal’s launch. Simon Adamson, an analyst at CreditSights, cautioned that unresolved questions regarding capital requirements and the legacy Credit Suisse bonds “are unlikely to be resolved soon and could continue to overhang UBS’s AT1 spreads.”

Nevertheless, UBS may benefit from broader market dynamics. The supply of new AT1 bonds in 2026 is expected to be limited, as many large global banks have only moderate refinancing needs. This scarcity could support solid demand for the UBS offering.

Management Reshuffle and Upcoming Milestones

The bond issuance coincides with internal changes at the top of the bank. Mike Dargan, the Group Chief Operations and Technology Officer, departed UBS at the end of December. The technology function now reports to Beatriz Martin in her new role as Group Chief Operating Officer, with Chris Gelvin assuming the technology leadership on an interim basis.

Investors are now looking ahead to several key dates. The bank is scheduled to release its quarterly earnings on February 4. Prior to that, the market will watch for signals from Bern regarding capital rules and monitor the repayment of $1.75 billion in senior bonds due on January 12.

Ad

UBS Stock: Buy or Sell?! New UBS Analysis from February 7 delivers the answer:

The latest UBS figures speak for themselves: Urgent action needed for UBS investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

UBS: Buy or sell? Read more here...

Tags: UBS
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Guaranty Bancshares Stock
Analysis

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
CrossFirst Bankshares Stock
Analysis

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Universal Insurance Stock
Analysis

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

February 7, 2026
Next Post
MP Materials Stock

MP Materials Stock Surges on Defense Department Agreement

Oracle Stock

Oracle Stock: A High-Stakes Bet on AI Ambition

Pfizer Stock

Pfizer's Strategic Pivot: A Year of Transition in Focus

Recommended

C3.ai Stock

Is C3.ai Stock Poised for a Rebound?

2 months ago
MMM stock news

Clarification on Hyperlink and Promotional Fees

2 years ago

XOMA Corporation Expands Portfolio with Acquisition of DSUVIA

2 years ago
Microsoft Stock

A Bold Bet: Peter Thiel’s Hedge Fund Doubles Down on Microsoft

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

ServiceNow Shares Face Market Skepticism Despite Record Performance

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Trending

Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

by SiterGedge
February 7, 2026
0

Avanos Medical is navigating a critical strategic transformation. The medical device firm is streamlining its operations to...

Guaranty Bancshares Stock

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth
  • Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion
  • Yirendai Charts a New Course with Tech-Driven Strategy

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com